STOCK TITAN

Ascendis Pharma A/S - ASND STOCK NEWS

Welcome to our dedicated news page for Ascendis Pharma A/S (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ascendis Pharma A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ascendis Pharma A/S's position in the market.

Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) will report its first quarter 2024 financial results and provide a business update on May 2, 2024. The company will host a conference call and live webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Ascendis Pharma A/S receives MHRA approval for YORVIPATH® in Great Britain for adults with chronic hypoparathyroidism, expanding global reach and gaining orphan drug status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary
Ascendis Pharma A/S executives to participate in fireside chat at Leerink Partners Global Biopharma Conference 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Summary
Ascendis Pharma A/S (ASND) announced the launch of TransCon™ PTH with full commercial availability in Germany and Austria, with the U.S. PDUFA date set for May 14, 2024. The company reported a total Q4 revenue of €138 million, including SKYTROFA® revenue of €64 million. It also provided a business update, highlighting the streamlined structure and processes, and the achievement of Vision 3x3. The financial results for Q4 2023 showed a significant increase in revenue and a decrease in R&D and SG&A expenses compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Ascendis Pharma A/S (ASND) executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be held virtually, with a live webcast available on the company's website. A webcast replay will also be accessible for 30 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Summary
Ascendis Pharma A/S (ASND) will report full year 2023 financial results and provide a business update on February 7, 2024, after the close of the U.S. financial markets. A conference call and webcast will be held at 4:30 p.m. Eastern Time (ET) to discuss the results. The live webcast link will be available on the Investors & News section of the Ascendis Pharma website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
conferences earnings
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) has announced the availability of YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy, in Germany and Austria. This marks the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially. The company aims to achieve regulatory approvals for three Endocrinology Rare Disease products by 2025 and aims for each to achieve blockbuster status by 2030. With an expanding commercial infrastructure, Ascendis Pharma is well positioned to meet the needs of physicians and patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) has formed and launched Eyconis, Inc. with Frazier Life Sciences to develop, manufacture, and commercialize TransCon ophthalmology assets globally. Eyconis has exclusive rights to develop and commercialize these products and Ascendis will receive milestone payments of up to $248 million, plus royalties on global net sales. The new company is led by industry veterans and is focused on addressing unmet medical needs in ophthalmology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
News
Rhea-AI Summary
Ascendis Pharma A/S (ASND) introduces 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. The company aims to achieve blockbuster status for multiple products and expand the engine for future innovation. Key updates include revenue expectations, product launches, and clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
none
Rhea-AI Summary
Ascendis Pharma A/S (ASND) and Specialised Therapeutics Asia Pte Ltd (ST) have signed an exclusive distribution agreement for three endocrinology therapies. Two of the therapies are already internationally approved, while the third is in development following successful Phase 2 data. The agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Ascendis Pharma A/S

Nasdaq:ASND

ASND Rankings

ASND Stock Data

8.01B
56.16M
0.76%
107.81%
5.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Denmark
Tuborg Boulevard 5

About ASND

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.